Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Rare Diseases Treatment Market, by Drug Type
1.4.2 Global Rare Diseases Treatment Market, by Distribution Channel
1.4.3 Global Rare Diseases Treatment Market, by Route of Administration
1.4.4 Global Rare Diseases Treatment Market, by Therapeutic Area
1.4.5 Global Rare Diseases Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
Chapter 4. Global Rare Diseases Treatment Market by Drug Type
4.1 Global Biologics Market by Region
4.2 Global Biosimilar Market by Region
4.3 Global Small Molecule Market by Region
Chapter 5. Global Rare Diseases Treatment Market by Distribution Channel
5.1 Global Specialty Pharmacy Market by Region
5.2 Global Hospital Pharmacy Market by Region
5.3 Global Online Pharmacy Market by Region
Chapter 6. Global Rare Diseases Treatment Market by Route of Administration
6.1 Global Injectable Market by Region
6.2 Global Oral Market by Region
6.3 Global Others Market by Region
Chapter 7. Global Rare Diseases Treatment Market by Therapeutic Area
7.1 Global Cancer Market by Region
7.2 Global Cardiovascular Conditions Market by Region
7.3 Global Infectious Diseases Market by Region
7.4 Global Musculoskeletal Conditions Market by Region
7.5 Global Endocrine Disorders Market by Region
7.6 Global Metabolic Disorders Market by Region
7.7 Global Hematologic Disorders Market by Region
7.8 Global Neurological Conditions Market by Region
7.9 Global Others Market by Region
Chapter 8. Global Rare Diseases Treatment Market by Region
8.1 North America Rare Diseases Treatment Market
8.1.1 North America Rare Diseases Treatment Market by Drug Type
8.1.1.1 North America Biologics Market by Country
8.1.1.2 North America Biosimilar Market by Country
8.1.1.3 North America Small Molecule Market by Country
8.1.2 North America Rare Diseases Treatment Market by Distribution Channel
8.1.2.1 North America Specialty Pharmacy Market by Country
8.1.2.2 North America Hospital Pharmacy Market by Country
8.1.2.3 North America Online Pharmacy Market by Country
8.1.3 North America Rare Diseases Treatment Market by Route of Administration
8.1.3.1 North America Injectable Market by Country
8.1.3.2 North America Oral Market by Country
8.1.3.3 North America Others Market by Country
8.1.4 North America Rare Diseases Treatment Market by Therapeutic Area
8.1.4.1 North America Cancer Market by Country
8.1.4.2 North America Cardiovascular Conditions Market by Country
8.1.4.3 North America Infectious Diseases Market by Country
8.1.4.4 North America Musculoskeletal Conditions Market by Country
8.1.4.5 North America Endocrine Disorders Market by Country
8.1.4.6 North America Metabolic Disorders Market by Country
8.1.4.7 North America Hematologic Disorders Market by Country
8.1.4.8 North America Neurological Conditions Market by Country
8.1.4.9 North America Others Market by Country
8.1.5 North America Rare Diseases Treatment Market by Country
8.1.5.1 US Rare Diseases Treatment Market
8.1.5.1.1 US Rare Diseases Treatment Market by Drug Type
8.1.5.1.2 US Rare Diseases Treatment Market by Distribution Channel
8.1.5.1.3 US Rare Diseases Treatment Market by Route of Administration
8.1.5.1.4 US Rare Diseases Treatment Market by Therapeutic Area
8.1.5.2 Canada Rare Diseases Treatment Market
8.1.5.2.1 Canada Rare Diseases Treatment Market by Drug Type
8.1.5.2.2 Canada Rare Diseases Treatment Market by Distribution Channel
8.1.5.2.3 Canada Rare Diseases Treatment Market by Route of Administration
8.1.5.2.4 Canada Rare Diseases Treatment Market by Therapeutic Area
8.1.5.3 Mexico Rare Diseases Treatment Market
8.1.5.3.1 Mexico Rare Diseases Treatment Market by Drug Type
8.1.5.3.2 Mexico Rare Diseases Treatment Market by Distribution Channel
8.1.5.3.3 Mexico Rare Diseases Treatment Market by Route of Administration
8.1.5.3.4 Mexico Rare Diseases Treatment Market by Therapeutic Area
8.1.5.4 Rest of North America Rare Diseases Treatment Market
8.1.5.4.1 Rest of North America Rare Diseases Treatment Market by Drug Type
8.1.5.4.2 Rest of North America Rare Diseases Treatment Market by Distribution Channel
8.1.5.4.3 Rest of North America Rare Diseases Treatment Market by Route of Administration
8.1.5.4.4 Rest of North America Rare Diseases Treatment Market by Therapeutic Area
8.2 Europe Rare Diseases Treatment Market
8.2.1 Europe Rare Diseases Treatment Market by Drug Type
8.2.1.1 Europe Biologics Market by Country
8.2.1.2 Europe Biosimilar Market by Country
8.2.1.3 Europe Small Molecule Market by Country
8.2.2 Europe Rare Diseases Treatment Market by Distribution Channel
8.2.2.1 Europe Specialty Pharmacy Market by Country
8.2.2.2 Europe Hospital Pharmacy Market by Country
8.2.2.3 Europe Online Pharmacy Market by Country
8.2.3 Europe Rare Diseases Treatment Market by Route of Administration
8.2.3.1 Europe Injectable Market by Country
8.2.3.2 Europe Oral Market by Country
8.2.3.3 Europe Others Market by Country
8.2.4 Europe Rare Diseases Treatment Market by Therapeutic Area
8.2.4.1 Europe Cancer Market by Country
8.2.4.2 Europe Cardiovascular Conditions Market by Country
8.2.4.3 Europe Infectious Diseases Market by Country
8.2.4.4 Europe Musculoskeletal Conditions Market by Country
8.2.4.5 Europe Endocrine Disorders Market by Country
8.2.4.6 Europe Metabolic Disorders Market by Country
8.2.4.7 Europe Hematologic Disorders Market by Country
8.2.4.8 Europe Neurological Conditions Market by Country
8.2.4.9 Europe Others Market by Country
8.2.5 Europe Rare Diseases Treatment Market by Country
8.2.5.1 Germany Rare Diseases Treatment Market
8.2.5.1.1 Germany Rare Diseases Treatment Market by Drug Type
8.2.5.1.2 Germany Rare Diseases Treatment Market by Distribution Channel
8.2.5.1.3 Germany Rare Diseases Treatment Market by Route of Administration
8.2.5.1.4 Germany Rare Diseases Treatment Market by Therapeutic Area
8.2.5.2 UK Rare Diseases Treatment Market
8.2.5.2.1 UK Rare Diseases Treatment Market by Drug Type
8.2.5.2.2 UK Rare Diseases Treatment Market by Distribution Channel
8.2.5.2.3 UK Rare Diseases Treatment Market by Route of Administration
8.2.5.2.4 UK Rare Diseases Treatment Market by Therapeutic Area
8.2.5.3 France Rare Diseases Treatment Market
8.2.5.3.1 France Rare Diseases Treatment Market by Drug Type
8.2.5.3.2 France Rare Diseases Treatment Market by Distribution Channel
8.2.5.3.3 France Rare Diseases Treatment Market by Route of Administration
8.2.5.3.4 France Rare Diseases Treatment Market by Therapeutic Area
8.2.5.4 Russia Rare Diseases Treatment Market
8.2.5.4.1 Russia Rare Diseases Treatment Market by Drug Type
8.2.5.4.2 Russia Rare Diseases Treatment Market by Distribution Channel
8.2.5.4.3 Russia Rare Diseases Treatment Market by Route of Administration
8.2.5.4.4 Russia Rare Diseases Treatment Market by Therapeutic Area
8.2.5.5 Spain Rare Diseases Treatment Market
8.2.5.5.1 Spain Rare Diseases Treatment Market by Drug Type
8.2.5.5.2 Spain Rare Diseases Treatment Market by Distribution Channel
8.2.5.5.3 Spain Rare Diseases Treatment Market by Route of Administration
8.2.5.5.4 Spain Rare Diseases Treatment Market by Therapeutic Area
8.2.5.6 Italy Rare Diseases Treatment Market
8.2.5.6.1 Italy Rare Diseases Treatment Market by Drug Type
8.2.5.6.2 Italy Rare Diseases Treatment Market by Distribution Channel
8.2.5.6.3 Italy Rare Diseases Treatment Market by Route of Administration
8.2.5.6.4 Italy Rare Diseases Treatment Market by Therapeutic Area
8.2.5.7 Rest of Europe Rare Diseases Treatment Market
8.2.5.7.1 Rest of Europe Rare Diseases Treatment Market by Drug Type
8.2.5.7.2 Rest of Europe Rare Diseases Treatment Market by Distribution Channel
8.2.5.7.3 Rest of Europe Rare Diseases Treatment Market by Route of Administration
8.2.5.7.4 Rest of Europe Rare Diseases Treatment Market by Therapeutic Area
8.3 Asia Pacific Rare Diseases Treatment Market
8.3.1 Asia Pacific Rare Diseases Treatment Market by Drug Type
8.3.1.1 Asia Pacific Biologics Market by Country
8.3.1.2 Asia Pacific Biosimilar Market by Country
8.3.1.3 Asia Pacific Small Molecule Market by Country
8.3.2 Asia Pacific Rare Diseases Treatment Market by Distribution Channel
8.3.2.1 Asia Pacific Specialty Pharmacy Market by Country
8.3.2.2 Asia Pacific Hospital Pharmacy Market by Country
8.3.2.3 Asia Pacific Online Pharmacy Market by Country
8.3.3 Asia Pacific Rare Diseases Treatment Market by Route of Administration
8.3.3.1 Asia Pacific Injectable Market by Country
8.3.3.2 Asia Pacific Oral Market by Country
8.3.3.3 Asia Pacific Others Market by Country
8.3.4 Asia Pacific Rare Diseases Treatment Market by Therapeutic Area
8.3.4.1 Asia Pacific Cancer Market by Country
8.3.4.2 Asia Pacific Cardiovascular Conditions Market by Country
8.3.4.3 Asia Pacific Infectious Diseases Market by Country
8.3.4.4 Asia Pacific Musculoskeletal Conditions Market by Country
8.3.4.5 Asia Pacific Endocrine Disorders Market by Country
8.3.4.6 Asia Pacific Metabolic Disorders Market by Country
8.3.4.7 Asia Pacific Hematologic Disorders Market by Country
8.3.4.8 Asia Pacific Neurological Conditions Market by Country
8.3.4.9 Asia Pacific Others Market by Country
8.3.5 Asia Pacific Rare Diseases Treatment Market by Country
8.3.5.1 China Rare Diseases Treatment Market
8.3.5.1.1 China Rare Diseases Treatment Market by Drug Type
8.3.5.1.2 China Rare Diseases Treatment Market by Distribution Channel
8.3.5.1.3 China Rare Diseases Treatment Market by Route of Administration
8.3.5.1.4 China Rare Diseases Treatment Market by Therapeutic Area
8.3.5.2 Japan Rare Diseases Treatment Market
8.3.5.2.1 Japan Rare Diseases Treatment Market by Drug Type
8.3.5.2.2 Japan Rare Diseases Treatment Market by Distribution Channel
8.3.5.2.3 Japan Rare Diseases Treatment Market by Route of Administration
8.3.5.2.4 Japan Rare Diseases Treatment Market by Therapeutic Area
8.3.5.3 India Rare Diseases Treatment Market
8.3.5.3.1 India Rare Diseases Treatment Market by Drug Type
8.3.5.3.2 India Rare Diseases Treatment Market by Distribution Channel
8.3.5.3.3 India Rare Diseases Treatment Market by Route of Administration
8.3.5.3.4 India Rare Diseases Treatment Market by Therapeutic Area
8.3.5.4 South Korea Rare Diseases Treatment Market
8.3.5.4.1 South Korea Rare Diseases Treatment Market by Drug Type
8.3.5.4.2 South Korea Rare Diseases Treatment Market by Distribution Channel
8.3.5.4.3 South Korea Rare Diseases Treatment Market by Route of Administration
8.3.5.4.4 South Korea Rare Diseases Treatment Market by Therapeutic Area
8.3.5.5 Singapore Rare Diseases Treatment Market
8.3.5.5.1 Singapore Rare Diseases Treatment Market by Drug Type
8.3.5.5.2 Singapore Rare Diseases Treatment Market by Distribution Channel
8.3.5.5.3 Singapore Rare Diseases Treatment Market by Route of Administration
8.3.5.5.4 Singapore Rare Diseases Treatment Market by Therapeutic Area
8.3.5.6 Malaysia Rare Diseases Treatment Market
8.3.5.6.1 Malaysia Rare Diseases Treatment Market by Drug Type
8.3.5.6.2 Malaysia Rare Diseases Treatment Market by Distribution Channel
8.3.5.6.3 Malaysia Rare Diseases Treatment Market by Route of Administration
8.3.5.6.4 Malaysia Rare Diseases Treatment Market by Therapeutic Area
8.3.5.7 Rest of Asia Pacific Rare Diseases Treatment Market
8.3.5.7.1 Rest of Asia Pacific Rare Diseases Treatment Market by Drug Type
8.3.5.7.2 Rest of Asia Pacific Rare Diseases Treatment Market by Distribution Channel
8.3.5.7.3 Rest of Asia Pacific Rare Diseases Treatment Market by Route of Administration
8.3.5.7.4 Rest of Asia Pacific Rare Diseases Treatment Market by Therapeutic Area
8.4 LAMEA Rare Diseases Treatment Market
8.4.1 LAMEA Rare Diseases Treatment Market by Drug Type
8.4.1.1 LAMEA Biologics Market by Country
8.4.1.2 LAMEA Biosimilar Market by Country
8.4.1.3 LAMEA Small Molecule Market by Country
8.4.2 LAMEA Rare Diseases Treatment Market by Distribution Channel
8.4.2.1 LAMEA Specialty Pharmacy Market by Country
8.4.2.2 LAMEA Hospital Pharmacy Market by Country
8.4.2.3 LAMEA Online Pharmacy Market by Country
8.4.3 LAMEA Rare Diseases Treatment Market by Route of Administration
8.4.3.1 LAMEA Injectable Market by Country
8.4.3.2 LAMEA Oral Market by Country
8.4.3.3 LAMEA Others Market by Country
8.4.4 LAMEA Rare Diseases Treatment Market by Therapeutic Area
8.4.4.1 LAMEA Cancer Market by Country
8.4.4.2 LAMEA Cardiovascular Conditions Market by Country
8.4.4.3 LAMEA Infectious Diseases Market by Country
8.4.4.4 LAMEA Musculoskeletal Conditions Market by Country
8.4.4.5 LAMEA Endocrine Disorders Market by Country
8.4.4.6 LAMEA Metabolic Disorders Market by Country
8.4.4.7 LAMEA Hematologic Disorders Market by Country
8.4.4.8 LAMEA Neurological Conditions Market by Country
8.4.4.9 LAMEA Others Market by Country
8.4.5 LAMEA Rare Diseases Treatment Market by Country
8.4.5.1 Brazil Rare Diseases Treatment Market
8.4.5.1.1 Brazil Rare Diseases Treatment Market by Drug Type
8.4.5.1.2 Brazil Rare Diseases Treatment Market by Distribution Channel
8.4.5.1.3 Brazil Rare Diseases Treatment Market by Route of Administration
8.4.5.1.4 Brazil Rare Diseases Treatment Market by Therapeutic Area
8.4.5.2 Argentina Rare Diseases Treatment Market
8.4.5.2.1 Argentina Rare Diseases Treatment Market by Drug Type
8.4.5.2.2 Argentina Rare Diseases Treatment Market by Distribution Channel
8.4.5.2.3 Argentina Rare Diseases Treatment Market by Route of Administration
8.4.5.2.4 Argentina Rare Diseases Treatment Market by Therapeutic Area
8.4.5.3 UAE Rare Diseases Treatment Market
8.4.5.3.1 UAE Rare Diseases Treatment Market by Drug Type
8.4.5.3.2 UAE Rare Diseases Treatment Market by Distribution Channel
8.4.5.3.3 UAE Rare Diseases Treatment Market by Route of Administration
8.4.5.3.4 UAE Rare Diseases Treatment Market by Therapeutic Area
8.4.5.4 Saudi Arabia Rare Diseases Treatment Market
8.4.5.4.1 Saudi Arabia Rare Diseases Treatment Market by Drug Type
8.4.5.4.2 Saudi Arabia Rare Diseases Treatment Market by Distribution Channel
8.4.5.4.3 Saudi Arabia Rare Diseases Treatment Market by Route of Administration
8.4.5.4.4 Saudi Arabia Rare Diseases Treatment Market by Therapeutic Area
8.4.5.5 South Africa Rare Diseases Treatment Market
8.4.5.5.1 South Africa Rare Diseases Treatment Market by Drug Type
8.4.5.5.2 South Africa Rare Diseases Treatment Market by Distribution Channel
8.4.5.5.3 South Africa Rare Diseases Treatment Market by Route of Administration
8.4.5.5.4 South Africa Rare Diseases Treatment Market by Therapeutic Area
8.4.5.6 Nigeria Rare Diseases Treatment Market
8.4.5.6.1 Nigeria Rare Diseases Treatment Market by Drug Type
8.4.5.6.2 Nigeria Rare Diseases Treatment Market by Distribution Channel
8.4.5.6.3 Nigeria Rare Diseases Treatment Market by Route of Administration
8.4.5.6.4 Nigeria Rare Diseases Treatment Market by Therapeutic Area
8.4.5.7 Rest of LAMEA Rare Diseases Treatment Market
8.4.5.7.1 Rest of LAMEA Rare Diseases Treatment Market by Drug Type
8.4.5.7.2 Rest of LAMEA Rare Diseases Treatment Market by Distribution Channel
8.4.5.7.3 Rest of LAMEA Rare Diseases Treatment Market by Route of Administration
8.4.5.7.4 Rest of LAMEA Rare Diseases Treatment Market by Therapeutic Area
Chapter 9. Company Profiles
9.1 AbbVie, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Acquisition and Mergers:
9.3 Bayer AG
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Approval and Trails:
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.6 Bristol Myers Squibb Company
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Acquisition and Mergers:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Acquisitions and Mergers:
9.8 AstraZeneca PLC
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisition and Mergers:
9.9 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisition and Mergers:
9.10. PTC Therapeutics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Acquisition and Mergers:
Unique Offerings 